Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology
Healthy:No
Age Range:Any
Updated:3/16/2019
Start Date:March 25, 2014
End Date:January 1, 2100

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples

This research trial studies whole exome sequencing in finding causative variants in germline
deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving
therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients
with congestive heart failure receiving therapy for breast cancer may help doctors learn more
about changes that occur in DNA and identify biomarkers related to congestive heart failure.

PRIMARY OBJECTIVES:

I. To identify, using next generation sequencing, rare variants of large effect size that
impact the risk of congestive heart failure (CHF) in patients from the clinical trial
ECOG-5103 (E5103).

OUTLINE:

Previously collected germline DNA samples are analyzed via whole exome sequencing.

Inclusion Criteria:

- European American patients with DNA available

- European American patients who developed CHF and patients who did not develop CHF
following a full course of treatment with an anthracycline and bevacizumab

- African American cases (based on a drop in left ventricular ejection fraction [LVEF] <
50 or a drop from baseline > 20 points) and African American controls
We found this trial at
1
site
Eastern Cooperative Oncology Group
Boston, Massachusetts 02215
Principal Investigator: Bryan P. Schneider
Phone: 317-274-6473
?
mi
from
Boston, MA
Click here to add this to my saved trials